Automated determination of 8-OHdG in cells and tissue via immunofluorescence using a specially created antibody.

8-OHdG Cancer DNA-damage Histology Immunostaining

Journal

Biotechnology reports (Amsterdam, Netherlands)
ISSN: 2215-017X
Titre abrégé: Biotechnol Rep (Amst)
Pays: Netherlands
ID NLM: 101637426

Informations de publication

Date de publication:
Jun 2024
Historique:
received: 01 08 2023
revised: 27 02 2024
accepted: 27 02 2024
medline: 1 7 2024
pubmed: 1 7 2024
entrez: 1 7 2024
Statut: epublish

Résumé

Despite powerful DNA repair systems, oxidative damage/modification to DNA is an inevitable side effect of metabolism, ionizing radiation, lifestyle habits, inflammatory pathologies such as type-2 diabetes or metabolic syndrome, cancer and natural aging. One of the most common oxidative DNA modifications is 8-OHdG (8‑hydroxy-2'-deoxyguanosine), which is the most widely used marker in research and clinical diagnostics. 8-OHdG is easily and specifically detectable in various samples such as urine, plasma, cells and tissues via a large variety of methods like ELISA, HPLC, chromatographic methods, and immunochemistry. Formed by oxidation of guanine and being representative for the degree of DNA damage, 8-OHdG can be also used as biomarker for risk assessment of various cancers as well as degenerative diseases. Here, we present a highly specific, self-developed 8-OHdG antibody in successful comparison to a commercially one, tested in cells (FF95, HCT116, and HT22) and intestinal tissue, focusing on automatized evaluation via fluorescence/confocal microscopy.

Identifiants

pubmed: 38948353
doi: 10.1016/j.btre.2024.e00833
pii: S2215-017X(24)00006-7
pmc: PMC11211097
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e00833

Informations de copyright

© 2024 The Authors. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Dirk Roggenbuck is an employee of and owns shares in GA Generic Assays and Medipan GmbH, diagnostic manufacturers. Marc Wegmann is an employee of GA Generic Assays and Medipan GmbH, diagnostic manufacturers.

Auteurs

Tobias Jung (T)

Department of Molecular Toxicology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Arthur-Scheunert-Allee 114-116 14558, Nuthetal, Germany.
German Center for Cardiovascular Research (DZHK), 10117, Berlin, Germany.

Nicole Findik (N)

new/era/mabs GmbH, August-Bebel-Str. 89 14482 Potsdam, Germany.

Bianca Hartmann (B)

new/era/mabs GmbH, August-Bebel-Str. 89 14482 Potsdam, Germany.

Katja Hanack (K)

new/era/mabs GmbH, August-Bebel-Str. 89 14482 Potsdam, Germany.
University of Potsdam, Department of Biochemistry and Biology, Chair of Immunotechnology, Karl-Liebknecht-Str. 24-25, Build 29, Office 1.55 14476 Potsdam, Germany.

Kai Grossmann (K)

GA Generic Assays GmbH, Germany.

Dirk Roggenbuck (D)

Faculty of Health Sciences Brandenburg, Brandenburg Technical University Cottbus-Senftenberg.

Marc Wegmann (M)

MEDIPAN GmbH, Ludwig-Erhard-Ring 3 15827 Dahlewitz.

René Mantke (R)

Brandenburg Medical School Theodor Fontane, Klinik für Allgemein- und Viszeralchirurgie, Klinikum Brandenburg, Hochstraße 29 14770 Brandenburg an der Havel, Germany.

Markus Deckert (M)

Brandenburg Medical School Theodor Fontane, Theodor Fontane Campus Brandenburg, Hämatologie, Onkologie SKB, IAG Psychoonkologie und Palliativversorgung, Hochstraße 29, 14770 Brandenburg an der Havel, Germany.

Tilman Grune (T)

Department of Molecular Toxicology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Arthur-Scheunert-Allee 114-116 14558, Nuthetal, Germany.
German Center for Cardiovascular Research (DZHK), 10117, Berlin, Germany.
German Center for Diabetes Research (DZD) 85764 Muenchen-Neuherberg, Germany.
NutriAct - Competence Cluster Nutrition Research Berlin-Potsdam, 14558 Nuthetal, Germany.
University of Potsdam, Institute of Nutrition 14558 Nuthetal, Germany.

Classifications MeSH